

GLAXOSMITHKLINE PLC  
Form 6-K  
August 06, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending August 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 3 August 2009 of an increase in the notional allocation of Ordinary share ADRs on 30 July 2009 at a price of \$ 38.43 per ADR:-

|                    |    |
|--------------------|----|
| Dr M M Slaoui      | 4  |
| Mrs C Bruck Slaoui | 1  |
| Mr E J Gray        | 15 |
| Mr W C Louv        | 9  |
| Dr D Pulman        | 17 |

This notification relates to a transaction notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

6 August  
2009

**SIGNATURES**

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: August 6 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc